DrugPatentWatch Database Preview
Drugs in Development Information for Amatuximab
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the drug development status for Amatuximab?
Amatuximab is an investigational drug.
There have been 4 clinical trials for Amatuximab.
The most recent clinical trial was a Phase 2 trial, which was initiated on December 1st 2008.
The most common disease conditions in clinical trials are Mesothelioma, Carcinoma, Non-Small-Cell Lung, and Carcinoma. The leading clinical trial sponsors are Morphotek, National Cancer Institute (NCI), and [disabled in preview].
Summary for Amatuximab
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2008-12-01) |
| Vendors | 0 |
Recent Clinical Trials for Amatuximab
| Title | Sponsor | Phase |
|---|---|---|
| Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). | Morphotek | Phase 2 |
| A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers | Morphotek | Phase 1 |
| Amatuximab for High Mesothelin Cancers | National Cancer Institute (NCI) | Phase 0 |
Clinical Trial Summary for Amatuximab
Top disease conditions for Amatuximab
Top clinical trial sponsors for Amatuximab
US Patents for Amatuximab
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
